FFC#5/2021

In vitro evaluation of novel sequence-specific RNA editing tools to rescue nonsense mutant CFTR transcript

AREA 1 Therapies to correct the underlying defect

FFC#5/2021

In vitro evaluation of novel sequence-specific RNA editing tools to rescue nonsense mutant CFTR transcript
€ 0 still needed
0%
€ 99.500 goal

pRINCIPAL INVESTIGATOR

Aldo Di Leonardo (Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche – STEBICEF, Università degli Studi di Palermo)

Researchers

4

Category

AREA 1 Therapies to correct the underlying defect

Duration

2 years

Goal

€ 99.500

Funds raised

€ 99.500

Objectives

Taking into consideration stop mutations, rarer than the more common F508del, this research project aims to develop a new site-specific gene-editing technique. The researchers propose the development and use of site-specific mRNA editing through the deamination of Adenosine into Inosine, a ribonucleotide recognized as guanosine by the ribosome, which would allow the correction of stop codons in the mRNA. This new editing technique involves the use of the REPAIRv2 system and antisense oligonucleotides (ASOs) specific to the mRNA region where the stop codon is present. The researchers propose to evaluate the effectiveness of the procedure on cellular models with molecular biology techniques such as real time-PCR, western blotting, immunofluorescence and sequencing.

XIX Convention FFC Ricerca – download here a brief presentation of the project

 

WHO ADOPTED THE PROJECT

Delegazione FFC Ricerca di Palermo e Trapani

€ 99.500

Gruppo di sostegno FFC Ricerca Genova “Mamme per la ricerca”

€ 50.000

Delegazione FFC Ricerca di Prato

€ 15.000

OTHER PROJECTS

Discover the other projects

GMRF#1/2026

Exploring the role of PKD1 in promoting CFTR stability and function at the cell surface

FFC#1/2026

Mapping proteins regulating CFTR mRNA stability to identify new therapeutic targets for nonsense mutations

FFC#2/2026

Evaluating the potential of phosphodiesterase inhibitors to enhance the efficacy of CFTR modulators and support personalized therapeutic approaches